Stapled Peptides Designed to Block Cancer-Driving Hippo Pathway in GI Tumors | Research

The takeaway

Rational design and hydrocarbon stapling improved TEAD-binding coactivator peptide affinity by over 5-fold, creating potential therapeutics targeting the Hippo signaling pathway in gastrointestinal cancers.

>5-fold affinity gain
Combining rational design with hydrocarbon stapling improved TEAD-binding peptide affinity over 5-fold while maintaining target specificity

What the researchers found

Rational design and all-hydrocarbon stapling of TEAD coactivator α-helix peptides improved binding affinity >5-fold by stabilizing helical structure (reducing indirect readout penalty) and optimizing interfacial residues (enhancing direct readout).

Why it matters

The Hippo pathway is dysregulated in many GI cancers but has been difficult to drug. Stapled peptides that block TEAD-coactivator interactions could fill this therapeutic gap, offering a new approach to hard-to-treat cancers.

The numbers in context

>5-fold affinity improvement; i to i+4 hydrocarbon staple; staple points outward; hydrogen bonds and hydrophobic contacts; alpha-helix and omega-loop hotspot sites

How the study worked

Computational and experimental study. Rational peptide design, all-hydrocarbon i, i+4 stapling modification, structural analysis, and binding affinity assays for TEAD-peptide interactions.

Who was studied

In vitro TEAD-peptide binding studies with X-ray crystallography

What this study cannot tell us

In vitro binding studies only. No cell-based or animal testing of anti-cancer activity. Stapled peptide delivery to intracellular targets in tumors remains a challenge. Cost of stapled peptide manufacturing.

How to read the evidence

Low evidence grade: computational design with in vitro binding validation only. No cellular or anti-tumor efficacy data.

When this study was published

Published 2021. Hippo pathway targeting and stapled peptide drug development continue to advance.

The bigger picture

Stapled peptides are an emerging drug class that bridges the gap between small molecules and biologics. This study demonstrates a systematic approach to designing stapled peptides against protein-protein interactions, applicable beyond TEAD to other "undruggable" cancer targets.

Questions still open

Can these stapled peptides enter GI cancer cells and inhibit Hippo signaling?
Would TEAD-targeting peptides synergize with existing GI cancer therapies?
Can the Ω-loop peptide be similarly optimized for dual-site TEAD blocking?

Common questions

What are stapled peptides?

Stapled peptides are short protein fragments reinforced with a chemical bridge (typically hydrocarbon "staple") that locks them into their active shape. This makes them more stable, better at binding targets, and potentially more drug-like than unmodified peptides.

Why target the Hippo pathway for cancer?

The Hippo pathway controls cell growth and death. When it malfunctions in GI cancers, cells grow uncontrollably. Blocking TEAD, a key component, could stop this cancer-driving signal — but TEAD has been very difficult to target with conventional drugs.

Read the original research

Rational design and chemical modification of TEAD coactivator peptides to target hippo signaling pathway against gastrointestinal cancers.

Journal of receptor and signal transduction research, 41(4), 408-415

View on PubMed ↗Publisher’s paper ↗

Citation

Gao, Shuxia; Wang, Yingchao; Ji, Lijuan. (2021). Rational design and chemical modification of TEAD coactivator peptides to target hippo signaling pathway against gastrointestinal cancers.. Journal of receptor and signal transduction research, 41(4), 408-415. https://doi.org/10.1080/10799893.2020.1818093